Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CORT Corcept医疗

盘前交易 09-14 05:31:36 EDT

112.79

-2.13

-1.85%

盘前110.00

-2.79-2.47%

04:36 EDT

最高117.84	最低109.30	成交量128.25万
今开115.22	昨收114.92	日振幅7.43%
总市值121.92亿	流通市值108.77亿	总股本1.08亿
成交额1.44亿	换手率1.33%	流通股本9,644万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept医疗","latestPrice":112.79,"timestamp":1789156800000,"preClose":114.92,"halted":0,"volume":1282453,"hourTrading":{"tag":"盘前","latestPrice":110,"preClose":112.79,"latestTime":"04:36 EDT","volume":14,"amount":1554.4699799999999,"timestamp":1789375018124,"change":-2.79,"changeRate":-0.024736,"amplitude":0.026864},"delay":0,"changeRate":-0.018534632788026414,"floatShares":96440095,"shares":108098397,"eps":0.453654,"marketStatus":"盘前交易","change":-2.13,"latestTime":"09-14 05:31:36 EDT","open":115.22,"high":117.84,"low":109.3,"amount":144052071.85525998,"amplitude":0.074313,"askPrice":119.99,"askSize":190,"bidPrice":91.55,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.453654,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":112.79,"preHourTrading":{"tag":"盘前","latestPrice":110,"preClose":112.79,"latestTime":"04:36 EDT","volume":14,"amount":1554.4699799999999,"timestamp":1789375018124,"change":-2.79,"changeRate":-0.024736,"amplitude":0.026864},"postHourTrading":{"tag":"盘后","latestPrice":112.79,"preClose":112.79,"latestTime":"19:59 EDT","volume":165185,"amount":18631214.1068,"timestamp":1789171176684,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.82339116248093,"impliedVol":0.3718,"impliedVolPercentile":0.036},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"1135039938","title":"Corcept医疗获Truist证券首次覆盖，给予“买入”评级，目标价上调至164美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135039938","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135039938?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:05","pubTimestamp":1787051111,"startTime":"0","endTime":"0","summary":"Truist Securities近日宣布，首次对Corcept医疗（Corcept Therapeutics）启动覆盖，并给予“买入”评级。这家华尔街机构设定的目标股价为164美元，与当前价位相比，释放出强烈的看多信号——毕竟此前市场普遍预期的目标价仅为50美元。这一鲜明对比，凸显出Truist对其未来增长潜力的高度信心。Corcept医疗作为一家专注于皮质醇调节疗法研发的生物制药公司，其核心产品在肿瘤学领域的应用前景正受到越来越多投资者的关注。此番评级上调，无疑为市场注入了新的想象空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4532","CORT","BK4007","FBT","LU0566484027.USD","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911935","title":"板块普涨之际 十只量化评分强劲的大盘医疗保健股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911935","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911935?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:27","pubTimestamp":1786462073,"startTime":"0","endTime":"0","summary":"经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。Centene Corporation以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics、Bright Spring Health Services紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics、Humana跻身前五，均获强烈“买入”评级。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303689","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MHIP","IE0004445239.USD","IE00B1XK9C88.USD","SG9999014880.SGD","IE000M9KFDE8.USD","IE00B19Z9P08.USD","LU1778281490.HKD","SG9999014906.USD","IE00B2B36J28.USD","LU1201861165.SGD","BK4581","LU0143551892.USD","LU2244417387.USD","LU0965509283.SGD","SG9999014914.USD","LU0882574055.USD","LU0432979614.USD","LU0980610538.SGD","FHLC","IE00B775H168.HKD","LU2461242641.AUD","LU2089283258.USD","EKG","LU1674673428.USD","LU0823416689.USD","IE0004445015.USD","LU1732800096.USD","PTH","UNH","LU0708994859.HKD","SG9999017495.SGD","LU1506573853.SGD","LU0198837287.USD","LU2552382058.USD","LU2361044865.SGD","LU0965509101.SGD","LU1074936037.SGD","LU0566484027.USD","IE00B7SZLL34.SGD","LU0251132253.USD","LU0072461881.USD","LU2954938101.SGD","BK4154","IE00B894F039.SGD","LU0320765489.SGD","BK4007","LU0353189763.USD","BK4613","IE0002141913.USD","LU0316494557.USD","LU1291159041.SGD","LU0128525929.USD","LU0353189680.USD","LU0158827781.USD","SG9999018865.SGD","LU0154245673.USD","LU2491050154.USD","LU0238689110.USD","LU0149725797.USD","LU1791710582.SGD","LU2111349929.HKD","LU2357305700.SGD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","IE00BKPKM429.USD","LU0820561818.USD","LU0943347566.SGD","LU2999663052.SGD","SGXZ81514606.USD","LU0048584097.USD","LU2552382132.HKD","LU1670627923.USD","LU0187121727.USD","LU2125154778.USD","SOLV","BK4534","SG9999014005.SGD","IXJ","IE00BZ1G4Q59.USD","LU2491050071.SGD","LU0052756011.USD","LU1066051225.USD","LU0345770993.USD","LU2279689827.SGD","LU1061106388.HKD","LU1119994496.HKD","LU1559883803.SGD","LU2362540622.SGD","BK4559","LU1548497426.USD","BK4196","LU0456855351.SGD","LU0949170772.SGD","LU1989764664.SGD","LU2065170008.USD","IE00B19Z9505.USD","IE00B7KXQ091.USD","LU0320765059.SGD","LU0965508806.USD","LU1093756325.SGD","LU0203347892.USD","BK4585","LU0320765992.SGD","LU0683600562.USD","IE0002270589.USD","LU0787776722.HKD","LU2324357040.USD","CORT","LU2087625088.SGD","BK4167","LU2361044949.HKD","IE00BFSS8Q28.SGD","LU2236285917.USD","LU0208291251.USD","LU0496365809.HKD","LU0058720904.USD","LU2125154935.USD","LU2112291526.USD","IE00B19Z9Z06.USD","LU1066051811.HKD","LU2468319806.SGD","LU0859254822.USD","IE00B4JS1V06.HKD","LU1323610961.USD","VHT","LU0079474960.USD","LU0256863811.USD","LGHT","LU0203345920.USD","BK4588","DVA","NBIX","SG9999002224.SGD","LU0545039389.USD","LU2211815571.USD","LU0053666078.USD","LU0130517989.USD","LU0122379950.USD","IE00BJJMRX11.SGD","LU2065171402.SGD","SG9999001176.USD","LU0661504455.SGD","SG9999018857.SGD","IE00BFXG1179.USD","LU2271345857.HKD","LU0158827948.USD","LU0170899867.USD","IE00B4R5TH58.HKD","LU2357627491.SGD","IE00BFSS7M15.SGD","LU1934455863.HKD","LU0965509010.AUD","LU0912757837.SGD","LU2242649171.HKD","BK4533","LU0130102774.USD","IE0005OL40V9.USD","IE00BZ9MQY76.HKD","LU0154245756.USD","LU0553294199.USD","LU0354030511.USD","LU0708995401.HKD","IE00BKVL7J92.USD","IE00BJJMRY28.SGD","LU1814569148.SGD","LU0289739699.SGD","LU1037948897.HKD","LU1674673691.USD","VEEV","LU0348723411.USD","BK4139","HALO","LU0861579265.USD","LU2552382215.SGD","LU1854104046.USD","LU2023251221.USD","LU1854103824.USD","LU0130518102.USD","TRUH","BK4532","LU1267930490.SGD","LU1914381329.SGD","LU1496350502.SGD","SGXZ31699556.SGD","LU0077335932.USD","LU0211326755.USD","LU2065169927.USD","SGXZ99366536.SGD","IE00B19Z8X17.USD","FXH","LU1988902786.USD","LU1934455194.USD","LU0795875169.SGD","SG9999001176.SGD","LU0795875086.SGD","SG9999014013.SGD","LU1791710400.SGD","LU0094547139.USD","PSCH","LU1064131342.USD","LU0345770308.USD","LU0310800379.SGD","LU2028103732.USD","LU1720051108.HKD","LU1699723380.USD","LU0128525689.USD","LU1066051498.USD","LU2462591277.SGD","LU1093756168.USD","LU0109394709.USD","BTSG","LU0211328371.USD","LU1732799900.SGD","LU2089984988.USD","LU0342679015.USD","UNHG","LU2133065610.SGD","SGXZ57979304.SGD","FBT","LU0477156953.USD","LU1267930730.SGD","LU1057294990.SGD","LU2360032135.SGD","LU1003077747.HKD","LU1066053197.SGD","SG9999002232.USD","LU0390134368.USD","CNCG","LU1989764748.USD","SG9999014021.USD","LU0029864427.USD","JDOC","IHF","IE00BWXC8680.SGD","BK4566","LU1670628061.USD","LU0689472784.USD","LU1201861249.SGD","SG9999014898.SGD","LU0310799852.SGD","LU1153585028.USD","LU0738911758.USD","LU0266013472.USD","LU0130103400.USD","LU0648001328.SGD","IYH","FFOX","SGXZ51526630.SGD","LU0234572021.USD","IE00B3T34201.USD","LU2362541273.HKD","LU2491049909.HKD","LU1934455277.USD","LU2089284900.SGD","LU1267930227.SGD","LU1718418525.SGD","LU2264538146.SGD","LU1720051017.SGD","LU1983260115.SGD","CNC","LU0354030438.USD","IE0009355771.USD","LU1983299246.USD","IE00BFTCPJ56.SGD","IE00B1BXHZ80.USD","LU0070302665.USD","HRTS","LU0114720955.EUR","SG9999013999.USD","HUM","BK4528","LU2347655156.SGD","LU0310800965.SGD","LU0557290698.USD","LU0820562030.AUD","LU0889565916.HKD","BK4504","RXL","IE0034235188.USD","LU2361045086.USD","LU0648000940.SGD","LU0162691827.USD","LU1037948541.HKD","LU0011850046.USD","IE00B19Z3581.USD","LU0107464264.USD","LU0211327993.USD","LU0672654240.SGD","IE00B19Z8W00.USD","LU2362541513.USD","LU0477156797.USD","LU2065171311.SGD","LU1989771016.USD","LU1023059063.AUD","LU0976567544.SGD","IE00BN29S564.USD","LU0528227936.USD","LU0417517546.SGD","LU1261432733.SGD","LU0211326839.USD","LU1551013342.USD","GDOC","LU0097036916.USD","BK4198","LU1069347547.HKD","LU0820561909.HKD","UNHW","LU0211331839.USD","LU1551013425.SGD","LU0053671581.USD","LU0109391861.USD","LU1267930573.SGD","LU1035773651.USD","LU1084165304.USD","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","XLV","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142339236","title":"异动解读｜Corcept医疗盘中下跌5.04%，报112.355美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142339236","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142339236?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:57","pubTimestamp":1785509857,"startTime":"0","endTime":"0","summary":"7月31日，Corcept医疗盘中下跌5.04%，报112.355美元/股，成交额4487.07万美元。Corcept医疗所在的制药行业中，个股中，礼来跌1.98%，诺和诺德跌8.94%，强生涨0.07%，施贵宝跌1.32%，辉瑞跌0.06%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155221462","title":"异动解读｜Corcept医疗盘中上涨15.98%，Q2业绩大幅超预期且上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1155221462","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155221462?lang=zh_cn&edition=full","pubTime":"2026-07-30 21:47","pubTimestamp":1785419235,"startTime":"0","endTime":"0","summary":"7月30日，Corcept医疗盘中上涨15.98%，报116.44美元/股，成交额9512.07万美元。公司同时上调全年营收指引至11亿至12亿美元，远高于此前9.5亿至10.5亿美元的预测及市场预期的9.995亿美元。业绩超预期主要受益于核心产品Korlym及新获批药物Lifyorli的商业化推进。此外，公司已于6月重新提交Relacorilant治疗库欣综合征的新药申请，Canaccord Genuity将目标价从135美元上调至150美元，进一步提振市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142994018","title":"异动解读｜Corcept医疗盘前上涨20.48%，Q2业绩大幅超预期且上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1142994018","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142994018?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:04","pubTimestamp":1785398675,"startTime":"0","endTime":"0","summary":"7月30日，Corcept医疗盘前上涨20.48%，报111.11美元/股，成交额8.01万美元。消息面上，公司公布第二季度财报，每股收益0.36美元，远超市场一致预期的0.02美元，同比增长24.14%；营收2.56亿美元，较去年同期1.94亿美元大幅增长，超出分析师预期约16%。业绩超预期主要受益于核心产品Korlym及新获批药物Lifyorli的商业化推进。此外，公司已于6月重新提交Relacorilant治疗库欣综合征的新药申请，Canaccord Genuity将目标价从135美元上调至150美元，进一步提振市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108389637","title":"异动解读｜Corcept医疗夜盘上涨20.02%，Q2业绩大幅超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1108389637","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108389637?lang=zh_cn&edition=full","pubTime":"2026-07-30 08:20","pubTimestamp":1785370834,"startTime":"0","endTime":"0","summary":"7月30日，Corcept医疗夜盘上涨20.02%，报111.56美元/股，成交额1159.29美元。消息面上，公司公布第二季度财报，每股收益0.36美元，远超市场一致预期的0.02美元，同比增长24.14%；营收2.56亿美元，较去年同期1.94亿美元大幅增长，超出分析师预期约16%。此外，公司已于6月重新提交Relacorilant治疗库欣综合征的新药申请，Canaccord Genuity将目标价从135美元上调至150美元，进一步提振市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept医疗夜盘上涨20.02%，Q2业绩大幅超预期且上调全年指引","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106250840","title":"Corcept医疗第二季度每股收益0.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106250840","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106250840?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:52","pubTimestamp":1785358322,"startTime":"0","endTime":"0","summary":"Corcept医疗第二季度营收达2.56147亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4532","PSCH","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156601194","title":"异动解读 | Corcept医疗盘后大涨18.34%，Q2业绩远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1156601194","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156601194?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:35","pubTimestamp":1785357345,"startTime":"0","endTime":"0","summary":"Corcept医疗在盘后交易中股价大涨18.34%，报110.0美元/股，成交额达到874.61万美元，引发市场广泛关注。消息面上，公司公布了第二季度财报，业绩表现大幅超出市场预期。此外，公司已于6月重新提交了Relacorilant用于治疗库欣综合征的新药申请，多条在研管线进展顺利，进一步提振了市场信心。同时，Canaccord Genuity也将Corcept医疗的目标价从135美元上调至150美元，显示出机构对公司未来前景的看好。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147544109","title":"异动解读｜Corcept医疗盘后上涨18.34%，Q2业绩大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1147544109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147544109?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:30","pubTimestamp":1785357042,"startTime":"0","endTime":"0","summary":"7月30日，Corcept医疗盘后上涨18.34%，报110.0美元/股，成交额874.61万美元。消息面上，公司公布第二季度财报，每股收益0.36美元，远超市场一致预期的0.00美元，同比增长24.14%；营收2.56亿美元，超出分析师预期的2.20亿美元约16.4%。业绩大幅超预期主要受益于核心产品Korlym及新获批药物Lifyorli的商业化推进。此外，公司已于6月重新提交Relacorilant治疗库欣综合征的新药申请，多条管线进展顺利，进一步提振市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167119674","title":"异动解读｜Corcept医疗盘中上涨5.36%，库欣综合征新药申请重新提交叠加财报预期提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1167119674","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167119674?lang=zh_cn&edition=full","pubTime":"2026-07-24 00:01","pubTimestamp":1784822508,"startTime":"0","endTime":"0","summary":"7月24日，Corcept医疗盘中上涨5.36%，报95.755美元/股，成交额2535.58万美元。消息面上，公司此前已完成候选药物Relacorilant用于治疗库欣综合征的新药申请重新提交，标志着该药物上市进程迈出关键一步。此外，公司核心产品Lifyorli联合白蛋白紫杉醇治疗铂耐药卵巢癌已于今年3月获得FDA正式批准，商业化落地持续推进。Corcept Therapeutics是一家商业阶段制药公司，致力于通过调节激素皮质醇的作用来治疗严重的内分泌、肿瘤、代谢和神经系统疾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134837674","title":"Corcept医疗重新提交新药申请，Relacorilant有望成为库欣综合征治疗新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1134837674","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134837674?lang=zh_cn&edition=full","pubTime":"2026-06-18 04:28","pubTimestamp":1781728098,"startTime":"0","endTime":"0","summary":"Corcept医疗已重新提交了其候选药物Relacorilant作为库欣综合征患者治疗手段的新药申请。这一举措标志着该公司在推进该药物上市进程中迈出了关键一步，旨在为这一罕见内分泌疾病患者提供新的治疗方案。库欣综合征是一种因体内皮质醇长期过量引起的复杂疾病，患者常面临一系列严重的健康挑战。若最终获得批准，该药物有望为目前治疗选择有限的患者群体带来新的希望，并可能在该治疗领域占据重要地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4532","CORT","LU1559883803.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157411460","title":"Corcept医疗曾于2021年11月收到司法部关于Korlym销售与推广的记录传票——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157411460","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157411460?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488322,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件披露，Corcept医疗公司曾在2021年11月收到美国司法部发出的记录传票，内容涉及该公司旗下药物Korlym的销售与推广活动。\n这一信息揭示了监管机构此前已对Corcept医疗的业务操作展开过调查。传票要求公司提供与Korlym相关的特定记录，表明司法部当时正在审查该药物的市场营销行为。\nKorlym是Corcept医疗的核心产品，用于治疗内源性库欣综合征。此次披露的传票事件，发生在近期其他监管动态之前，为理解该公司面临的整体监管环境提供了更多背景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4532","BK4007","LU1559883803.SGD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176930516","title":"美国司法部、加州保险局及原告各州决定不介入针对Corcept医疗的诉讼——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1176930516","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176930516?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488319,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）的一份文件披露，美国司法部、加利福尼亚州保险局以及作为原告的多个州，已决定不介入针对Corcept医疗（Corcept Therapeutics）提起的相关诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4532","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125500114","title":"Corcept医疗将重新提交新药申请，寻求Relacorilant用于库欣综合征治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1125500114","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125500114?lang=zh_cn&edition=full","pubTime":"2026-05-27 20:00","pubTimestamp":1779883242,"startTime":"0","endTime":"0","summary":"Corcept医疗宣布，将就其药物Relacorilant用于治疗库欣综合征患者的新药申请进行重新提交。此举旨在应对监管机构的反馈，并推动该疗法获得批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136026732","title":"异动解读 | Piper Sandler上调目标价，Corcept医疗盘中大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136026732","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136026732?lang=zh_cn&edition=full","pubTime":"2026-05-01 22:05","pubTimestamp":1777644341,"startTime":"0","endTime":"0","summary":"Corcept医疗（CORT）今日盘中股价大幅上涨5.33%，引起了市场关注。消息面上，根据路透社报道，华尔街券商Piper Sandler将Corcept Therapeutics Inc的目标价从73美元上调至88美元。分析师上调目标价通常被视为对公司未来前景的积极信号，可能增强了投资者信心，从而推动了股价上涨。该股在交易时段内表现强劲，反映出市场对此次分析师评级调整的积极反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180318588","title":"Corcept医疗将公布第一季度财报 同步举行企业进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1180318588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180318588?lang=zh_cn&edition=full","pubTime":"2026-04-24 04:07","pubTimestamp":1776974822,"startTime":"0","endTime":"0","summary":"Corcept医疗（CORT）即将发布2024年第一季度财务业绩报告，届时公司将披露最新经营动态，并通过电话会议与投资者深度交流。此次会议将涵盖财务数据解读、研发管线进展及战略规划等关键议题，为市场提供全面评估企业价值的重要窗口。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4532","BK4007","LU1559883803.SGD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184877931","title":"Corcept在SGO重磅会议公布Rosella关键试验完整数据：《柳叶刀》同步发表Lifyorli™联合白蛋白紫杉醇显著延长铂耐药卵巢癌患者总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1184877931","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184877931?lang=zh_cn&edition=full","pubTime":"2026-04-11 04:46","pubTimestamp":1775853973,"startTime":"0","endTime":"0","summary":"Corcept医疗（Corcept Therapeutics）于美国妇科肿瘤学会（SGO）年会重磅环节公布了其关键性Rosella试验的完整数据，同时国际顶级医学期刊《柳叶刀》同步发表了相关研究成果。研究证实，其创新药物Lifyorli™（relacorilant）联合白蛋白紫杉醇治疗方案，能够显著改善铂类药物耐药性卵巢癌患者的总生存期。\n这一突破性进展为缺乏有效治疗手段的铂耐药卵巢癌患者提供了新的希望，也彰显了靶向皮质醇调节疗法在肿瘤治疗领域的应用潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","BK4532","BK4007","LU1559883803.SGD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153014349","title":"FDA批准Corcept医疗选择性糖皮质激素受体拮抗剂Lifyorli™（Relacorilant）联合白蛋白紫杉醇用于铂耐药卵巢癌患者治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153014349","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153014349?lang=zh_cn&edition=full","pubTime":"2026-03-26 00:45","pubTimestamp":1774457116,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式批准Corcept医疗公司研发的选择性糖皮质激素受体拮抗剂Lifyorli与白蛋白紫杉醇联合用药方案，用于治疗铂类耐药卵巢癌患者。这一重大进展为面临治疗困境的患者提供了新的希望。Lifyorli通过精准阻断糖皮质激素受体的活性，有效抑制肿瘤对化疗药物的耐药机制。与白蛋白紫杉醇的协同使用，有望显著提升晚期卵巢癌患者的临床应答率。此次批准标志着靶向激素通路治疗卵巢癌领域的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","LU0566484027.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135304921","title":"FDA批准Relacorilant联合白蛋白紫杉醇治疗铂耐药上皮性卵巢癌、输卵管癌或原发性腹膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1135304921","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135304921?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:36","pubTimestamp":1774449374,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准Relacorilant与白蛋白紫杉醇（Nab-Paclitaxel）联合用药方案，用于治疗铂类药物耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。这一重大监管进展为面临有限治疗选择的晚期妇科癌症患者提供了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","CORT","LU0566484027.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517986458","title":"Corcept医疗盘中异动 股价大跌5.05%报56.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517986458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517986458?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:50","pubTimestamp":1741121452,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时50分，Corcept医疗股票出现异动，股价大幅下跌5.05%。截至发稿，该股报56.09美元/股，成交量149.598万股，换手率1.42%，振幅6.96%。Corcept医疗股票所在的生物技术行业中，整体跌幅为0.16%。Corcept医疗公司简介：Corcept Therapeutics Inc是一家商业阶段的制药公司，致力于通过调节激素皮质醇的作用来发现和开发治疗严重代谢、肿瘤和神经精神疾病的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305045053abe85a69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305045053abe85a69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4007","LU1559883803.SGD","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.3604},{"period":"6month","weight":2.5082},{"period":"1year","weight":0.5174},{"period":"ytd","weight":2.2411}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Corcept Therapeutics Incorporated于1998年5月13日在特拉华州注册成立。该公司是一家商业阶段公司，从事发现和开发药物，通过调节激素皮质醇的作用来治疗严重的内分泌、肿瘤、代谢和神经系统疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.048323},{"month":7,"riseRate":0.478261,"avgChangeRate":0.007526},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.006443},{"month":9,"riseRate":0.434783,"avgChangeRate":0.059257},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept医疗","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corcept医疗(CORT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corcept医疗,CORT,Corcept医疗股票,Corcept医疗股票老虎,Corcept医疗股票老虎国际,Corcept医疗行情,Corcept医疗股票行情,Corcept医疗股价,Corcept医疗股市,Corcept医疗股票价格,Corcept医疗股票交易,Corcept医疗股票购买,Corcept医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept医疗(CORT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corcept医疗(CORT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}